BRPI0413826A - processo de tratamento de cáncer com inibidores de hdac - Google Patents
processo de tratamento de cáncer com inibidores de hdacInfo
- Publication number
- BRPI0413826A BRPI0413826A BRPI0413826-0A BRPI0413826A BRPI0413826A BR PI0413826 A BRPI0413826 A BR PI0413826A BR PI0413826 A BRPI0413826 A BR PI0413826A BR PI0413826 A BRPI0413826 A BR PI0413826A
- Authority
- BR
- Brazil
- Prior art keywords
- hdac inhibitors
- pharmaceutical compositions
- present
- methods
- mesothelioma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Steroid Compounds (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US10/665,079 US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
PCT/US2004/027943 WO2005018578A2 (en) | 2003-08-26 | 2004-08-26 | Method of treating cancer with hdac inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413826A true BRPI0413826A (pt) | 2006-10-24 |
Family
ID=34556614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413826-0A BRPI0413826A (pt) | 2003-08-26 | 2004-08-26 | processo de tratamento de cáncer com inibidores de hdac |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090012175A1 (ja) |
EP (2) | EP1663194B1 (ja) |
JP (2) | JP4338734B2 (ja) |
KR (1) | KR100924737B1 (ja) |
CN (1) | CN102188415A (ja) |
AT (1) | ATE462426T1 (ja) |
AU (1) | AU2004266169B9 (ja) |
BR (1) | BRPI0413826A (ja) |
CA (1) | CA2535806C (ja) |
DE (1) | DE602004026321D1 (ja) |
DK (1) | DK1663194T3 (ja) |
EC (1) | ECSP066452A (ja) |
ES (1) | ES2345775T3 (ja) |
HR (1) | HRP20060080A2 (ja) |
IL (1) | IL173846A0 (ja) |
MA (1) | MA28209A1 (ja) |
NO (1) | NO328575B1 (ja) |
NZ (2) | NZ560485A (ja) |
PL (2) | PL379887A1 (ja) |
PT (1) | PT1663194E (ja) |
RU (1) | RU2356547C2 (ja) |
SI (1) | SI1663194T1 (ja) |
WO (1) | WO2005018578A2 (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
EP1487426B1 (en) * | 2002-03-04 | 2012-08-22 | Sloan-kettering Institute For Cancer Research | Methods of inducing terminal differentiation |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
JP2006523693A (ja) * | 2003-04-01 | 2006-10-19 | メモリアル スローン−ケタリング キャンサー センター | ヒドロキサム酸化合物およびその使用方法 |
US7901675B2 (en) * | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
NZ599464A (en) | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
CN101495116A (zh) | 2005-03-22 | 2009-07-29 | 哈佛大学校长及研究员协会 | 蛋白降解病症的治疗 |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
JP5108750B2 (ja) | 2005-05-13 | 2012-12-26 | トポターゲット ユーケー リミテッド | Hdac阻害剤の医薬製剤 |
TWI365068B (en) * | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
GB0518720D0 (en) * | 2005-09-14 | 2005-10-19 | Hamlet Pharma Ab | Therapeutic combination |
JP2009514889A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためにsaha及びボルテゾミブを用いる方法 |
AU2006311829B8 (en) * | 2005-11-04 | 2013-02-21 | Merck Sharp & Dohme Corp. | Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies |
WO2007056243A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co. Inc. | Methods of treating cancers with saha and fluorouracil and other combination therapies |
WO2007054719A2 (en) | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
JP5409015B2 (ja) | 2006-02-14 | 2014-02-05 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ヒストンデアセチラーゼ阻害剤 |
WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
US20100137239A1 (en) | 2006-04-24 | 2010-06-03 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
EA017198B1 (ru) | 2006-10-30 | 2012-10-30 | Хрома Терапьютикс Лтд. | Гидроксаматы в качестве ингибиторов гистон-деацетилазы |
EP2086323A4 (en) * | 2006-11-03 | 2010-01-06 | Univ Maryland | METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA |
CN101801994A (zh) | 2006-12-29 | 2010-08-11 | 格洛斯特制药公司 | 制备Romidepsin |
MX2010003230A (es) * | 2007-09-25 | 2010-04-07 | Topotarget Uk Ltd | Metodos para la sintesis de ciertos compuestos de acido hidroxamico. |
WO2009064300A1 (en) * | 2007-11-15 | 2009-05-22 | The Johns Hopkins University | Combinations of hdac inhibitors and cytokines/growth factors |
ES2536208T3 (es) * | 2008-03-07 | 2015-05-21 | Onxeo Dk, Branch Of Onxeo S.A., France | Métodos de tratamiento que emplean infusión continua prolongada de Belinostat |
RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
US8883851B2 (en) | 2008-10-15 | 2014-11-11 | Generics [Uk] Limited | Process for the preparation of vorinostat |
NZ593585A (en) | 2008-11-26 | 2012-12-21 | Generics Uk Ltd | Crystalline forms of vorinostat (suberoylanilide hydroxamic acid) |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
US20120190817A2 (en) | 2010-07-12 | 2012-07-26 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
PL2614369T3 (pl) * | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
CN102846611A (zh) * | 2011-09-24 | 2013-01-02 | 复旦大学 | 斯克瑞泰Scriptaid在制备治疗创伤性脑损伤疾病药物中的用途 |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
CN103169807A (zh) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | 一种中西组合药物在制药中的应用 |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
WO2015190700A1 (ko) * | 2014-06-11 | 2015-12-17 | 성균관대학교산학협력단 | 패혈증 예방 또는 치료용 약학적 조성물 |
CN111195249B (zh) * | 2018-11-20 | 2023-11-28 | 深圳微芯生物科技股份有限公司 | 西达本胺联合r-chop的应用及联合药物 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5608108A (en) | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
EP0855024A4 (en) | 1995-09-20 | 2001-08-22 | Merck & Co Inc | HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
CZ20011342A3 (cs) | 1998-10-13 | 2001-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Cyklické tetrapeptidy |
JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
EA007649B1 (ru) | 1999-09-08 | 2006-12-29 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч | Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение |
WO2001038322A1 (en) | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
AU2001248701A1 (en) | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
WO2002022133A1 (en) * | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
AU2001290131B2 (en) | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
AU2002243231A1 (en) * | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US7314953B2 (en) * | 2001-03-27 | 2008-01-01 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
WO2002102323A2 (en) * | 2001-06-14 | 2002-12-27 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
AU2003219803B8 (en) * | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
EP1487426B1 (en) * | 2002-03-04 | 2012-08-22 | Sloan-kettering Institute For Cancer Research | Methods of inducing terminal differentiation |
CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
JP2006523693A (ja) * | 2003-04-01 | 2006-10-19 | メモリアル スローン−ケタリング キャンサー センター | ヒドロキサム酸化合物およびその使用方法 |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
-
2004
- 2004-08-26 DK DK04782425.5T patent/DK1663194T3/da active
- 2004-08-26 NZ NZ560485A patent/NZ560485A/en not_active IP Right Cessation
- 2004-08-26 CN CN201110072778XA patent/CN102188415A/zh active Pending
- 2004-08-26 AU AU2004266169A patent/AU2004266169B9/en active Active
- 2004-08-26 BR BRPI0413826-0A patent/BRPI0413826A/pt not_active IP Right Cessation
- 2004-08-26 AT AT04782425T patent/ATE462426T1/de active
- 2004-08-26 KR KR1020067003748A patent/KR100924737B1/ko not_active IP Right Cessation
- 2004-08-26 WO PCT/US2004/027943 patent/WO2005018578A2/en active IP Right Grant
- 2004-08-26 PL PL379887A patent/PL379887A1/pl unknown
- 2004-08-26 NZ NZ54593504A patent/NZ545935A/xx not_active IP Right Cessation
- 2004-08-26 EP EP04782425A patent/EP1663194B1/en active Active
- 2004-08-26 JP JP2006524891A patent/JP4338734B2/ja not_active Expired - Fee Related
- 2004-08-26 CA CA002535806A patent/CA2535806C/en not_active Expired - Fee Related
- 2004-08-26 RU RU2006109467/14A patent/RU2356547C2/ru not_active IP Right Cessation
- 2004-08-26 PL PL04782425T patent/PL1663194T3/pl unknown
- 2004-08-26 PT PT04782425T patent/PT1663194E/pt unknown
- 2004-08-26 ES ES04782425T patent/ES2345775T3/es active Active
- 2004-08-26 DE DE602004026321T patent/DE602004026321D1/de active Active
- 2004-08-26 EP EP10158245A patent/EP2201947A3/en not_active Withdrawn
- 2004-08-26 SI SI200431448T patent/SI1663194T1/sl unknown
-
2006
- 2006-02-21 IL IL173846A patent/IL173846A0/en unknown
- 2006-02-23 HR HR20060080A patent/HRP20060080A2/xx not_active Application Discontinuation
- 2006-02-23 MA MA28833A patent/MA28209A1/fr unknown
- 2006-03-23 EC EC2006006452A patent/ECSP066452A/es unknown
- 2006-03-24 NO NO20061348A patent/NO328575B1/no not_active IP Right Cessation
-
2008
- 2008-07-08 US US12/217,843 patent/US20090012175A1/en not_active Abandoned
- 2008-09-11 JP JP2008232889A patent/JP4914411B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413826A (pt) | processo de tratamento de cáncer com inibidores de hdac | |
WO2005039498A3 (en) | Methods of treating cancer with hdac inhibitors | |
TW200510375A (en) | New compounds | |
SE0200979D0 (sv) | New compounds | |
WO2003075839A3 (en) | Methods of inducing terminal differentiation | |
EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
MY140840A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
TNSN07322A1 (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
CY1110659T1 (el) | Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος | |
EA200400707A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
IT1307786B1 (it) | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. | |
TW200728296A (en) | Chemical compounds | |
FR2908131B1 (fr) | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique | |
SE0203817D0 (sv) | New composition | |
EP1912963A4 (en) | CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
EA200701741A1 (ru) | Композиция, содержащая окаперидон | |
EA200400709A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
EA200501366A1 (ru) | Лекарственное средство |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/185; A61P 35/00 Ipc: A61K 31/185 (2011.01), A61P 35/00 (2011.01) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2268 DE 24/06/2014. |